In transgenic rodent models of AD, liraglutide or exendin-4 treatment has been associated with a reduction in the amyloid plaque burden [62,72,76,77,78] and tau phosphorylation [56,58,67,72,73,79], which are considered invariable pathogenic factors underlying neurodegeneration in AD. The gene discussed is MAPT; the disease is Alzheimer disease.